Voyager: Recent Neurocrine Deal Signals More Upside

Risk comes from not knowing what you are doing. - Warren Buffett

Author's Note:?This is an abbreviated version of an article originally published in advance on Jan. 12, inside Integrated BioSci Investing for our members. I wrote this article?in response to research requests from our members.

As you can see, it takes roughly $1B to fund a drug from bench research to commercialization in the span of seven to ten years. As such, the company is likely to raise multiple rounds of capital via a public offering. Hence, you'd want to invest in biotech stocks with a significant market cap size. I prefer companies that are worth roughly $1B. After all, a significant equity offering won't clobber the share price of your stocks.

Now, certain companies, despite their smaller size, are still worthwhile speculative bets. Nevertheless, they tend to have significant partnerships to absorb the operating expenses. Voyager Therapeutics (NASDAQ:VYGR) is one such exception to my general rule. I believe that this small company has promising innovations for gene therapy. In this research, I'll feature a fundamental analysis of Voyager while focusing on the recent Neurocrine (NBIX) deal.

YOU CAN EITHER READ THE 1)?FREE ARTICLE?ON SEEKING ALPHA OR 2)?IN-DEPTH ANALYSIS?INSIDE INTEGRATED BIOSCI INVESTING.